Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04721223 | JAB-3068 Activity in Adult Patients With Advanced Solid Tumors | PHASE1 | COMPLETED | 12 | — | — | Apr 26, 2021 | Dec 29, 2023 | Sep 19, 2024 | 3 | China |
Incidence of dose limiting toxicities (DLTs) . A DLT is defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first treatment cycle with JAB-3068 and JS001.
ORR is defined as the proportion of participants with complete response or partial response (CR+PR).
| Arm | Type | Description |
|---|---|---|
| JAB-3068+PD1 inhibitor Part1 | EXPERIMENTAL | JAB-3068+JS001 dose escalation |
| JAB-3068+PD1 inhibitor Part2 | EXPERIMENTAL | JAB-3068+JS001 dose expansion |
| Name | Type | Description |
|---|---|---|
| JAB-3068 | DRUG | JAB-3068 administrated orally as a tablet. |
| PD1 inhibitor | DRUG | JS001 administrated as an intravenous(IV) infusion. |
Inclusion Criteria: * Written informed consent, according to local guidelines, signed and dated by the participant prior to the performance of any study-specific procedures, sampling, or analyses. * Participant must be ≥18 years of age at the time of signature of the informed consent form (ICF). * ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |